Organisation paid for research Program year 2021 Source: CMS Open Payments

Aurora FDRC Inc

Neither a doctor nor a teaching hospital

Research payments

$360,410

100 payments

Through program year 2021, Aurora FDRC Inc is reported as receiving $360,410 in research payments, across 100 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$22,071	13
2020	Research	$162,241	48
2019	Research	$176,098	39

Breakdown

Who paid Research payments · program years 2019–2021

Allergan Inc. $328,875 78 payments
Kowa Research Institute, Inc. $24,948 20 payments
Gilead Sciences, Inc. $6,587 2 payments

Studies the money was for Research payments · program years 2019–2021

A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $148,393 20 payments
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis $78,901 18 payments
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure $31,958 10 payments
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) $30,690 10 payments
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) $19,028 11 payments
K-877-302 $16,608 9 payments
K-877-302 $8,340 11 payments
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $7,428 2 payments
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis $4,946 2 payments
A Phase 1b/2a study in A Phase 1b/2a Study in Participants with Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation $4,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.